New Movement Disorders Clinic

Toronto Memory Program is proud to launch our newest clinic specializing in movement disorders such as Parkinson’s disease and tremor.

Learn More

  • New and Cutting Edge Clinical Research Trials

    Bringing the latest clinical research trials to the Scottsdale area.

  • Diversity & Inclusion

    Removing the health care disparities in our communities by bringing treatment options to a growing and diverse population.

  • Volunteer Participation

    We're always looking for participants to help participate in our clinical research trials.

  • About Us

    The Toronto Memory Program is Canada's most experienced site for drug treatment trials in Alzheimer's disease and related conditions.

    Learn More
  • Physicians

    To refer patients for consultation to our Memory Clinic, click Learn More.

    Learn More
  • Sponsors

    Partner with a leading clinical trials site with a strong track record of success and a commitment to excellence.

    Learn More
  • Help & Donate

    Please support the Toronto Memory Program Fund for Education to provide education to patients, caregivers, and the community.

    Learn More

Meet Our Medical Director

Dr. Sharon Cohen, the Director of the Toronto Memory Program, is a Canadian-trained Neurologist specializing in behaviour and cognition, as well as an internationally recognized expert in this field. Dr. Cohen is an assistant professor in the University of Toronto's Division of Neurology and Graduate Department of Speech Language Pathology.

Learn More

Dr. Sharon Cohen

Our Clinical Trials

What is a Clinical Trial?

Clinical research is the scientifically accepted method for determining whether medications or devices are safe, tolerable, and effective to treat a specific condition. Clinical trials in humans occur only after evaluation of a treatment in the laboratory and in animal studies.

Through clinical trials, doctors find new and better ways to prevent, detect, diagnose, control, treat and cure illnesses. Clinical trials are dependent on the participation of volunteers, who join with scientists, to make advances in medicine possible.

We are committed to providing the highest quality of clinical research in Canada for the following conditions and more:

-Alzheimer's Disease

-Mild Cognitive Impairment

-Parkinson's Disease

-Lewy Body Dementia

-Alzheimer's Disease Prevention


View Current Studies Contact Us

Alzheimer's disease

With over 700,000 Canadians living with Alzheimer’s disease, finding successful new treatments is more crucial than ever. At Toronto Memory Program, we specialize in Alzheimer’s disease prevention, diagnosis and the use of currently approved treatments. However, we need patients, and the public, to partner with us by participating in clinical trials to move forward potential new treatments  If you are interested in learning more about our current enrolling clinical trials, visit our Current Studies page for more information.

View Current Studies Contact Us

Mild Cognitive Impairment

Mild Cognitive Impairment (MCI) is a term used to describe a mild degree of cognitive decline along with a preservation of independent function.  Identifying the cause of MCI early is important to preserve cognition and optimize treatment. MCI is a risk factor for progression to dementia.   Learn more about our MCI & Early Alzheimer’s disease enrolling trials by clicking the Current Studies tab.


View Current Studies Contact Us

Parkinson's disease

Parkinson’s is a chronic degenerative neurological disease caused by a loss of dopamine producing cells in the brain. Currently, more than 100,000 Canadians are living with Parkinson’s disease and with no cure. That's why we need your help!

Check out information about our Movement Disorder Clinic and our Current Studies page to learn more about how we are doing our part to combat Parkinson's disease.

View Current Studies Contact Us

Lewy Body dementia

Lewy Body dementia is a common form of dementia. In addition to cognitive symptoms other features such as fluctuations, visual hallucinations, Parkinson-like  symptoms, and acting out out dreams may be prominent. If you are experiencing these symptoms, or have been diagnosed with Lewy Body Dementia, click on our current studies tab and learn more about our clinical trials.

View Current Studies Contact Us

Alzheimer's disease prevention

Our best hope for managing Alzheimer’s disease is to either prevent it from happening or delay the onset of symptoms. Clinical trials at this stage try to disrupt the root causes and keep healthy people healthy. If you are interested in learning more about our current enrolling prevention trials, visit our Current Studies page for more information

View Current Studies Contact Us


New and better treatments for migraine management are needed. Many individuals continue to suffer from often debilitating headaches that significantly affect their quality of life. To learn more about Migraine treatment trials click on the Current Studies icon below.

View Current Studies Contact Us

Proudly Partnered With

"Our experience with the Toronto Memory Program has been entirely remote due to COVID but that did not stop the team from providing thorough, responsive, timely service. Everyone from the researchers to the support staff to Dr. Cohen himself has been incredibly informative and kind. We hope to be with the program for a while as we pursue clinical trials and we could not be more impressed by the team at TMP who will lead the way. Thank you for your important work! " - Annie White
"The experience at the clinic was great. Julie was especially wonderful, enthusiastic, clear, concise and just a wonderful representative of the clinic. She made the whole experience enjoyable and she put you at ease and made you comfortable right away." - Sue MacEachern
"I just wanted to thank you and everyone at the Toronto Memory Program for all your work and dedication. The care and service my mother received has been tremendous. She has a follow up in about nine months time, but I never got a chance to thank Dr. Sharon & Ian Cohen plus the entire team." - Gil Eany

In the Media

Dr. Sharon Cohen, Medical Director and Principal Investigator at Toronto Memory Program, discusses the exciting news that FDA has approved the use of aducanumab.

The first new treatment for Alzheimer’s disease in 20 years and the very first disease-modifying drug proven to slow AD progression.

Watch Video View All Media